Member Info for Badsterman

Just an aside from the brickbats and Guident wait;

"LUCY has announced strong preliminary Q1 2026 results, reflecting continued momentum across its expanding smart eyewear portfolio.

The Company reported approximately $0.81 million in preliminary Q1 2026 sales, representing a 78% increase year-over-year and marking the highest first-quarter revenue in company history. This performance extends Innovative Eyewear’s streak to 11 consecutive quarters of year-over-year revenue growth, with Q1 acceleration outpacing its already impressive 63% full-year 2025 growth rate.

Driven by demand across its portfolio of smart eyewear brands including Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer®, the Company continues to capitalize on the growing adoption of AI-enabled and audio-integrated wearable technology. "

I know it's now a heavily diluted holding, but maybe there is life in the old gal yet. 🤣

Https://www.linkedin.com/posts/kzg-hms-ugcPost-7452601992759332864-cAmh?utm_source=share&utm_medium=member_android&rcm=ACoAAD8YrFoBRGY9l7TjGKfko1g3to2DSV7p7z0

Work at Alexander Bay, looks like concrete pads in readiness for new equipment.

Fair point Ray, but...

A quick search reveals plenty of published research and peer reviewed science (I could find more).

Integrated Design of a Membrane-Lytic Peptide-Based Intravenous Nanotherapeutic Suppresses Triple-Negative Breast Cancer" - Published in Advanced Science (2022) regarding the CLX001 project.

"Development of membrane-active peptide therapeutics in oncology" - Published in the Journal of Peptide Science (2023), covering the development of CLX001.

VAL401 Peer-Reviewed Article - Published in the European Journal of Drug Metabolism and Pharmacokinetics (2018/2019), detailing results of the Phase II trial for lung cancer treatment.

Investegate

Epigenomics Publication - Research published in Epigenomics regarding the enhancement of Carboplatin efficacy in prostate cancer.

The Globe and Mail

Patient-Derived Cancer Models Data - Published data presented at AACR (2026), showcasing a framework for digital avatars with patient-derived cancer models for precision oncology.

Our Corporate Development Manager should have quite an armoury of science to backup his sales effort, yet he's delivered nothing.

They are presenting to the American Cancer Research Society in San Diego tomorrow. I'm sure our favourite Corporate Development Manager will be along for the ride. He's been with Valirx for 5 years and 7 months - that's a lot of salary for no return.

Valirx continue to partner with cutting edge research teams on a multitude of different projects and they also deliver an awful lot of presentations, all without any commercial interest. Seriously, why is that?

(I'm sure there will be any number of sarcastic, non-funny responses - so save them for another thread. 👍)

It's quiet on the newsfront Freddie,

Although METIR did announce three new distributors, Aptamer are providing binders for their pathogen detectors.

Goes on to make the case for investment via a chart!!

Snake oil salesman.

Ha, says he hasn't even read the RNS from Friday. Then go

I don't see how Jennings can promise to deliver progress on 2A and Aftan when both issues sit with third party decision makers; the DRME and Nambian Special Court of Arbitration.

Geoff Eyre was previously CEO at Hummingbird and Jennings will be looking to protect his investment.

Not sure I like this news....let's see what Mr Market thinks. 🤔

Jennings just posted on Telegram to say he's "laser focused on delivery" but won't say much online, for obvious reasons.

GLA.

Feels to me like a few crumbs to suck in newbies prior to the inevitable raise at 0.2.

Nothing from Ambrose (they have been hiring recently), or VoxCell?

Variants of the word "commercial" are used seven times but still no actual cash. 🤫

Easy to be cynical Nom,

But Mark is networking at the highest level backed up by peer reviewed articles.

It's certainly a step up in class from the previous regime.

It's the hope that kills portfolios.🤪

TEK has always had a fluctuating discount to NAV, generally about 50%, or more.

Couple that with Cliff's penchant for a fund raise, I'd say a big percentage of the Guident IPO is already priced in.

With the exception of SALT (43p IPO), all the Listed companies either trade at less than IPO price, have suffered multiple dilutions or gone bust.

The rampers and AI content generators seem to ignore these seemingly fatal flaws in TEK's trading history.

This is an AI response to the issue;

Tekcapital's shares are trading at a significant discount to their Net Asset Value (NAV), currently around 45-66%. There are a few reasons for this:

- *Investor uncertainty*: Tekcapital's portfolio companies, such as Guident, are in growth stages and may not be generating significant revenue yet, creating uncertainty around their valuations.

- *Market sentiment*: The investment company sector has faced challenges, leading to a general discount in share prices.

- *Lack of liquidity*: Tekcapital's shares may not be as liquid as other investments, contributing to the discount.

- *Portfolio concentration*: The company's portfolio is concentrated in a few key companies, such as Microsalt and Guident, making it sensitive to their performance.

AI is utterly hopeless as it does not mention the constant fundraising, dilution or bankrupt companies (BELL) amongst the portfolio.

I wouldn't trust AI to write a shopping list.

Market won't care for this RNS, it's a company owned by an Aptamer insider that has no revenue. Just another drain on cash reserves.

I'm most interested in updates about the AZ/Unilever collabs as we've heard nothing for months.

His ChatGPT has gone into sulk mode because it got hoodwinked by Clever Cliff.

Perhaps the IPO is on hold whilst TEK consider a huge cash offer for Guident and we'll all get a special dividend.

🐖 🐷 might 🪰

Bill,

I reckon Wozzer's AI🐂 💩 generator has run out of TEK superlatives.

To be fair to Porky, he has called the raises quite accurately in the past.

Whereas, all you rampers still have no income to show for many years of 🐎💩 predictions about commercialising assets.

Maybe this year....🤔

Trusted,

I think you're spot on,

My hope for 15p has been destroyed by this latest raise. The sly old Cliffox has caught me napping.

Salt slipping sub 50p today, they are overpriced given modest future revenues. Lucy nearly at all-time lows, GENIP way below IPO price and BELL gone bust.

Guident IPO seems to be stuck in the mud, yet we've got the Wazzock telling us the future is great @8p!!

I reckon there'll be a queue to get out of this at 12p, me included.

I wish I'd never heard of Clifford Gross.

Sunak conveniently forgets that Brexit cost the UK millions in Horizon funding, a programme we've now rejoined.

In 2024 Starmer announced £520 million for the Life Sciences Innovative Manufacturing Fund (LSIMF) to support investments in medicine, diagnostics, and medical device manufacturing.

What ever your opinion of Starmer he has already "got his finger out" regarding UK biotech.

Indeed Dog,

Why has Cliff raised now? Is it because he knows Guident will be delayed, or has failed to raise enough capital?

Any US investors doing relatively simple due diligence would uncover Cliff's poor track record.

Are the underwriters struggling to get the Guident IPO over the line?

Perhaps US investors are shunning the Guident IPO once they've done their due diligence on Cliff's track record.

I wish I'd have took a small loss at 11.5p rather than wait for this seemingly doomed IPO.

Another Gross disaster. 🙄